drugset / Trial / NCT07104617
Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the safety, and preliminary antitumor activity of TY-302 combined with Abiraterone tablets in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
Timeline
- Start
- 2025-08
- Primary completion
- 2026-10
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tamoxifen | Small molecule | 75 mg | Oral |
| Subject | Tamoxifen | Small molecule | 100 mg | Oral |
| Background | Abiraptor | Unknown | 1000 mg | Oral |